Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged ≥6 to \<12 years~2. Clinical history of SAR (at least 2 years) with exacerbations during the study season for the relevant seasonal allergen (e.g., tree/grass pollen)~3. Demonstrated sensitivity to at least 1 seasonal allergen through positive skin prick test within 12 months prior to screening~4. A 12-hour rTNSS value ≥6 out of a possible 12 for the morning assessment at screening~5. Signed informed consent/assent form (subject and parent/caregiver/legal guardian)~Exclusion Criteria:~1. Females of childbearing potential or pregnant~2. Plans to travel outside the known pollen area for the investigational site for 24 hours or longer during the last 7 days of the run-in period.~3. History of anaphylaxis and/or other severe local reaction(s) to skin testing~4. History and evidence of acute or significant chronic sinusitis or chronic purulent post nasal drip~5. Subjects with an active pulmonary disorder or infection.~6. Subjects with posterior subcapsular cataracts or glaucoma

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
- GSP 301 Placebo NS (Type: PLACEBO_COMPARATOR): GSP 301 Placebo nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).